Dable Habib J 4

What Happened

Dable Habib J, an Outside Director of SpyGlass Pharma, was granted a derivative award covering 27,400 shares on February 5, 2026. The Form 4 lists an acquisition price of $0.00 per share (no cash paid at grant). This was a compensation grant (not an open-market purchase or sale) and the securities are subject to a vesting schedule.

Key Details

• Transaction date: February 5, 2026; Form 4 filed February 9, 2026 (filed 4 days after the transaction).
• Transaction type: Grant / derivative award (coded "A"); 27,400 shares @ $0.00.
• Shares owned after transaction: Not disclosed in the filing.
• Vesting/footnote: Per footnote F1, the award vests 1/36th each month following the February 5, 2026 grant date, subject to the Reporting Person remaining an Outside Director.
• Filing timeliness: Filed after the transaction date (late relative to the typical two-business-day Form 4 deadline).

Context

This was a director compensation grant (an option-like award with a monthly 36-month vesting schedule). Such grants align pay with continued service and do not represent an immediate purchase or sale of stock; they only convert into economic value if and when vested and exercised (and depending on strike/market price). Retail investors should watch future Form 4s for exercises or subsequent sales that show any realized insider buying or selling.